What Remiges Ventures does

Remiges Ventures is a privately held drug discovery venture capital firm founded in 2014 by Taro Inaba, operating a cross-border model with offices in Seattle, Cambridge, and Tokyo. The firm invests in early-stage biotechnology and pharmaceutical companies globally, with a strategic specialization in translating Japanese academic drug discovery innovations into globally viable ventures. Its core activity is leading or co-leading Series A financings for early-stage drug discovery companies across North America, Europe, Japan, and Israel, while also creating de novo companies based on intellectual property sourced from Japanese universities including the University of Tokyo and Kyoto Prefectural University of Medicine. The firm has backed 20+ portfolio companies spanning oncology, neurodegeneration, ophthalmology, infectious disease, and rare disease therapeutics, including Kupando, Immunis, Cyrano Therapeutics, ENB Therapeutics, Omeicos Therapeutics, Glycomine, and Capacity Bio.

Remiges operates through three fund vehicles with cumulative capital of approximately $275 million: Remiges BioPharma Fund I ($80M, 2014–2017), Remiges BioPharma Fund II ($95M, 2021), and the RDiscovery Fund ($100M, 2025–2026). The firm generates revenue through standard VC mechanics — management fees on committed/invested capital and carried interest on portfolio exits — and does not charge portfolio companies for investment services. In 2021 it established RDiscovery KK as a wholly-owned Tokyo incubation subsidiary that operates the RDiscovery Fund at the pre-startup stage, creating IP, forming ventures, and supporting translational science prior to traditional Series A financing.

The LP base is concentrated among major Japanese pharmaceutical companies (Taiho Pharmaceutical, Sumitomo Dainippon Pharma, Senju Pharmaceutical, EA Pharma) plus US/global strategic investors (Bristol-Myers Squibb, 1Globe Capital), Japan's sovereign fund Japan Investment Corporation, and diversified Japanese corporates (FUJIFILM, Toray Industries). The firm holds NEDO and AMED government certifications, which grant access to Japanese grant programs for technology-based biotech startups. The senior team combines US venture finance experience with Japanese pharma R&D and clinical development expertise, enabling the cross-border sourcing, diligence, and operational support that defines Remiges' investment approach.

Name

Remiges Ventures

Legal name

REMIGES Ventures

Website

https://remigesventures.com

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

11–50 employees

Short description

Remiges Ventures is a privately held, cross-border drug discovery venture capital firm founded in 2014 that leads early-stage biotech investments and creates new companies from Japanese academic IP, operating through approximately $275M in fund vehicles and an incubation subsidiary in Tokyo.

Ownership category

akta.pro rank

Product category

Venture Capital / Life Sciences Investment

NAICS

Portfolio Management and Investment Advice (523940), Other Investment Pools and Funds (5259)

SIC

Investment Advice (6282)

akta.pro primary industry

Venture Capital Fund-of-Funds / Multi-Manager Platforms (FSANAAAJ)

Keywords

• Drug discovery venture capital
• Biotech early-stage investment
• Life sciences venture fund
• Academic technology commercialization
• Cross-border biotech investing

Headquarters

HQ city

Cambridge

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D

Revenue model

1. Fund Management Fees: Generates revenue through management fees charged on funds under management, typically a percentage of committed capital during the investment period.
2. Carried Interest: Earns carried interest (performance fees) from fund returns when portfolio companies achieve successful exits through IPOs or acquisitions.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Remiges Ventures is a drug discovery venture capital firm that invests in early-stage biotechnology companies through multiple venture funds and creates de novo companies based on Japanese academic intellectual property via its RDiscovery incubation subsidiary in Tokyo. The firm manages Remiges BioPharma Fund ($80M), Remiges BioPharma Fund II ($95M), and RDiscovery Fund ($100M), with a focus on bridging Japanese academic innovations to the global biotech ecosystem.

Product overview

Remiges Ventures is a drug discovery venture capital firm with offices in Japan and the United States. The firm operates through multiple venture funds (Remiges BioPharma Fund at $80M, Remiges BioPharma Fund II at $95M) and an incubation structure (RDiscovery Fund at $100M managed by subsidiary RDiscovery KK). The funds invest in early-stage drug discovery companies globally, with a focus on bridging Japanese academic innovations to the global biotech ecosystem through lead investments, hands-on support, and new company creation.

Differentiator

Problem solved

Functional benefit

Brands

• RDiscovery Fund: A venture fund focused on drug discovery incubation, promoting VC-led translational science and new company formation for advanced drug discovery technologies from academia, research institutions, and pharmaceutical companies
• RDiscovery

Products and services

• Remiges BioPharma Fund Remiges Ventures' first venture fund focused on early-stage drug discovery and development companies, with $80 million total capital raised from Japanese pharmaceutical companies, US investors, and academic institutions such as Sumitomo Dainippon Pharma, Taiho Pharmaceutical, 1Globe Capital, and UTokyo Innovation Platform.
• Remiges BioPharma Fund II Remiges Ventures' second venture fund with $95 million total capital, investing in early-stage drug discovery companies and company creation based on Japanese academic innovations. Limited partners include Taiho Pharmaceutical, Sumitomo Dainippon Pharma, Bristol-Myers Squibb, 1Globe Capital, EA Pharma, and Senju Pharmaceutical.
• RDiscovery Fund A drug discovery incubation fund managed by RDiscovery KK, Remiges Ventures' Tokyo-based incubation subsidiary. The fund promotes VC-led translational science and new company formation for advanced drug discovery technologies from academia, research institutions, and pharmaceutical companies, reaching $100 million total. LPs include Japan Investment Corporation, ClavystBio, FUJIFILM Corporation, Senju Pharmaceutical, Toray Industries, Shin Nippon Biomedical Laboratories, 1Globe Health, and GW2050 PROJECTS companies.
• RDiscovery KK (RDiscovery Co., Ltd.) Remiges Ventures' wholly-owned incubation subsidiary in Tokyo, Japan that operates the RDiscovery Fund and provides pre-startup support, invests in scientific discoveries prior to startup formation, creates intellectual property, establishes and supports drug discovery ventures, and connects Japanese innovations to the global value chain.

Quantifiable outcome

• Created 6 de novo companies based on Japanese academic IP
• +2 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Scale indicators5 records

Recent moves10 records

Expansion highlights5 records

Direct peers

• Atlas Venture: Early-stage biotech-focused venture firm building companies from academic science; comparable to Remiges in its company-creation model and Series A focus, though based in the US/EU rather than Japan.
• Versant Ventures: Healthcare-dedicated venture firm with Inception Sciences for company creation from academic IP; closely comparable model of building biotech startups de novo and leading Series A rounds.
• ARCH Venture Partners: US-based biotech-focused VC investing in early-stage platform technologies from academia; comparable in taking academic IP and building companies, but at much larger fund scale.
• 5AM Ventures: Early-stage life-sciences VC focused on forming companies around academic and entrepreneur-sourced platforms; similar fund size and Series A focus to Remiges.
• MPM Capital: Biotech-dedicated firm investing in early-stage therapeutics with hands-on company building; shares Remiges' academic-to-startup conversion thesis and sector focus.
• SR One (GSK): Biotech-focused venture arm of GSK investing in early-stage therapeutics with strategic pharma LP model; comparable to Remiges' pharma-backed LP base and Series A lead strategy.
• Beyond Next Ventures: Japan-based early-stage VC with strong focus on deep tech and biotech from Japanese academia; the closest direct Japan-domiciled competitor for Japanese academic seed-stage deals.

Broad incumbents

• OrbiMed: Global healthcare investment platform across venture, growth, and public equities; comparable healthcare/biotech focus but with much broader mandate and larger AUM.
• JIC Capital (Japan Investment Corporation): Sovereign-backed venture capital arm of Japan Investment Corporation investing across Japanese deep tech and biotech; both an LP in RDiscovery Fund and a potential competitor/partner for Japanese academic spinouts.

Regional players

• ClavystBio: Singapore-based life sciences investor (Temasek-backed) that is also an LP in Remiges' RDiscovery Fund; competes in the broader Asia biotech venture ecosystem with larger scale and Southeast Asia orientation.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles19 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments24 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Remiges Ventures